78 related articles for article (PubMed ID: 21699803)
1. No impact of hepatitis C virus infection on mortality among drug users during the first decade after seroconversion.
Grady B; van den Berg C; van der Helm J; Schinkel J; Coutinho R; Krol A; Prins M
Clin Gastroenterol Hepatol; 2011 Sep; 9(9):786-792.e1. PubMed ID: 21699803
[TBL] [Abstract][Full Text] [Related]
2. Impact of hepatitis C virus infection on all-cause and liver-related mortality in a large community-based cohort of inner city residents.
Grebely J; Raffa JD; Lai C; Kerr T; Fischer B; Krajden M; Dore GJ; Tyndall MW
J Viral Hepat; 2011 Jan; 18(1):32-41. PubMed ID: 20196806
[TBL] [Abstract][Full Text] [Related]
3. Mortality in HIV-infected injection drug users with active vs cleared hepatitis C virus-infection: a population-based cohort study.
Omland LH; Jepsen P; Weis N; Christensen PB; Laursen AL; Nielsen H; Krarup H; Sørensen HT; Obel N
J Viral Hepat; 2010 Apr; 17(4):261-8. PubMed ID: 19709359
[TBL] [Abstract][Full Text] [Related]
4. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study.
Omland LH; Krarup H; Jepsen P; Georgsen J; Harritshøj LH; Riisom K; Jacobsen SE; Schouenborg P; Christensen PB; Sørensen HT; Obel N;
J Hepatol; 2010 Jul; 53(1):36-42. PubMed ID: 20400197
[TBL] [Abstract][Full Text] [Related]
5. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study.
Kielland KB; Skaug K; Amundsen EJ; Dalgard O
J Hepatol; 2013 Jan; 58(1):31-7. PubMed ID: 22960427
[TBL] [Abstract][Full Text] [Related]
6. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975.
Rodger AJ; Roberts S; Lanigan A; Bowden S; Brown T; Crofts N
Hepatology; 2000 Sep; 32(3):582-7. PubMed ID: 10960453
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region.
Di Napoli A; Pezzotti P; Di Lallo D; Petrosillo N; Trivelloni C; Di Giulio S;
Am J Kidney Dis; 2006 Oct; 48(4):629-37. PubMed ID: 16997059
[TBL] [Abstract][Full Text] [Related]
8. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study.
Bruno S; Zuin M; Crosignani A; Rossi S; Zadra F; Roffi L; Borzio M; Redaelli A; Chiesa A; Silini EM; Almasio PL; Maisonneuve P
Am J Gastroenterol; 2009 May; 104(5):1147-58. PubMed ID: 19352340
[TBL] [Abstract][Full Text] [Related]
9. Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities.
Hagan H; Pouget ER; Williams IT; Garfein RL; Strathdee SA; Hudson SM; Latka MH; Ouellet LJ
J Infect Dis; 2010 Feb; 201(3):378-85. PubMed ID: 20053137
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus reinfection in injection drug users.
Grebely J; Conway B; Raffa JD; Lai C; Krajden M; Tyndall MW
Hepatology; 2006 Nov; 44(5):1139-45. PubMed ID: 17058216
[TBL] [Abstract][Full Text] [Related]
11. Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Miller CL; Johnston C; Spittal PM; Li K; Laliberté N; Montaner JS; Schechter MT
Hepatology; 2002 Sep; 36(3):737-42. PubMed ID: 12198668
[TBL] [Abstract][Full Text] [Related]
12. Impact of HCV infection on first cadaveric renal transplantation, a single center experience.
Lin HH; Huang CC; Huang JY; Yang CW; Wu MS; Fang JT; Yu CC; Chiang YJ; Chu SH
Clin Transplant; 2004 Jun; 18(3):261-6. PubMed ID: 15142046
[TBL] [Abstract][Full Text] [Related]
13. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
[TBL] [Abstract][Full Text] [Related]
14. Sexual and other noninjection risks for HBV and HCV seroconversions among noninjecting heroin users.
Neaigus A; Gyarmathy VA; Zhao M; Miller M; Friedman SR; Des Jarlais DC
J Infect Dis; 2007 Apr; 195(7):1052-61. PubMed ID: 17330797
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of hepatitis C infection after liver transplantation.
Gane EJ; Portmann BC; Naoumov NV; Smith HM; Underhill JA; Donaldson PT; Maertens G; Williams R
N Engl J Med; 1996 Mar; 334(13):815-20. PubMed ID: 8596547
[TBL] [Abstract][Full Text] [Related]
16. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
17. Mortality in siblings of patients coinfected with HIV and hepatitis C virus.
Hansen AB; Gerstoft J; Kronborg G; Pedersen C; Sorensen HT; Obel N
J Infect Dis; 2007 Jan; 195(2):230-5. PubMed ID: 17191168
[TBL] [Abstract][Full Text] [Related]
18. Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Peles E; Schreiber S; Rados V; Adelson M
J Addict Med; 2011 Sep; 5(3):214-20. PubMed ID: 21844836
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
[TBL] [Abstract][Full Text] [Related]
20. The incidence and risk factors of community-acquired hepatitis C in a cohort of Italian blood donors.
Prati D; Capelli C; Silvani C; De Mattei C; Bosoni P; Pappalettera M; Mozzi F; Colombo M; Zanella A; Sirchia G
Hepatology; 1997 Mar; 25(3):702-4. PubMed ID: 9049222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
